These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31170218)

  • 1. Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.
    Gastaldi G; Gomes D; Schneiter P; Montet X; Tappy L; Clément S; Negro F
    PLoS One; 2019; 14(6):e0217751. PubMed ID: 31170218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents.
    Gualerzi A; Bellan M; Smirne C; Tran Minh M; Rigamonti C; Burlone ME; Bonometti R; Bianco S; Re A; Favretto S; Bellomo G; Minisini R; Carnevale Schianca GP; Pirisi M
    PLoS One; 2018; 13(12):e0209216. PubMed ID: 30571711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Elhelbawy M; Abdel-Razek W; Alsebaey A; Hashim M; Elshenawy H; Waked I
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):16-23. PubMed ID: 30024489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
    Kawano A; Shigematsu H; Miki K; Ichiki Y; Morita C; Yanagita K; Takahashi K; Dohmen K; Nomura H; Ishibashi H; Shimoda S
    Intern Med; 2018 Jun; 57(11):1533-1542. PubMed ID: 29321441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Type 2 diabetes mellitus, insulin resistance and hepatocellular carcinoma in chronic hepatitis C patients.
    Lombay B; Szilágyi R; Szalay F
    Orv Hetil; 2019 Oct; 160(40):1591-1602. PubMed ID: 31565976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.
    Teegen EM; Dürr M; Maurer MM; Eurich F; Vollbort A; Globke B; Bahra M; Blaeker H; Pratschke J; Eurich D
    Transpl Infect Dis; 2019 Feb; 21(1):e13020. PubMed ID: 30375710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C.
    Hengst J; Falk CS; Schlaphoff V; Deterding K; Manns MP; Cornberg M; Wedemeyer H
    J Infect Dis; 2016 Dec; 214(12):1965-1974. PubMed ID: 27683821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
    Laurito MP; Silva GF; Cheinquer H; Sharma R; Verna E; Parise ER
    Arq Gastroenterol; 2018; 55(2):179-183. PubMed ID: 30043870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
    Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
    Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.
    Abd El-Wahab EW; Mikheal A; Sidkey F; Shatat HZ
    J Med Virol; 2015 Mar; 87(3):428-40. PubMed ID: 25583244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
    Gerber L; Estep M; Stepanova M; Escheik C; Weinstein A; Younossi ZM
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):156-64.e3. PubMed ID: 26241510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure.
    Lim TR; Hazlehurst JM; Oprescu AI; Armstrong MJ; Abdullah SF; Davies NP; Flintham R; Balfe P; Mutimer DJ; McKeating JA; Tomlinson JW
    Clin Endocrinol (Oxf); 2019 Mar; 90(3):440-448. PubMed ID: 30586166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of hepatitis c virus infection status with serum glucose levels.
    Li Y; Wang X; Yu G; Sun H; Lv J; Chi X; Wu R; Gao X; Niu J
    BMC Gastroenterol; 2019 Jun; 19(1):86. PubMed ID: 31195990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.